Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
- Conditions
- Myelofibrosis
- Registration Number
- NCT02784496
- Lead Sponsor
- M.D. Anderson Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria:<br><br> 1. Currently enrolled in study 2007-0169 and benefiting from therapy as determined by<br> treating physician<br><br> 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at<br> enrollment of this study<br><br> 3. Ability and agreement to attend protocol-specified visits at the study site<br><br> 4. Able to comprehend and willing to sign the informed consent form<br><br> 5. Negative pregnancy test in females of childbearing potential; male patients with<br> female partners of child-bearing potential and female patients of childbearing<br> potential are required to use two forms of acceptable contraception, including one<br> barrier method, during their participation in the study and for 30 days following<br> last dose; acceptable forms of contraception include 1 highly effective method such<br> as an intrauterine device (IUD), hormonal (birth control pills, injections, or<br> implants), tubal ligation, or partner's vasectomy and at least 1 additional approved<br> barrier method such as a latex condom, diaphragm, or cervical cap; female patients<br> of childbearing potential must not be breast-feeding or planning to breast feed and<br> must have a negative pregnancy test 7 days before first study treatment<br><br>Exclusion Criteria:<br><br> 1. none
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of adverse events
- Secondary Outcome Measures
Name Time Method